effects of oral l-carnitine supplementation on lipid profile, anemia, and quality of life in chronic renal disease patients under hemodialysis a randomized, double-blinded, placebo-controlled trial英文论文.pdfVIP

Hindawi Publishing Corporation Journal of Nutrition and Metabolism Volume 2012, Article ID 510483, 6 pages doi:10.1155/2012/510483 Clinical Study Effects of Oral L-Carnitine Supplementation on Lipid Profile, Anemia, and Quality of Life in Chronic Renal Disease Patients under Hemodialysis: A Randomized, Double-Blinded, Placebo-Controlled Trial Afsoon Emami Naini,1 Mahnaz Moradi,1 Mojgan Mortazavi,1 Asghar Amini Harandi,2 Mehdi Hadizadeh,1 Farhad Shirani,1 Hamed Basir Ghafoori,3 and Pardis Emami Naini1 1 Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan 8168798847, Iran 2 Biochemistry Department, School of Medicine, Jahrom University of Medical Sciences, Jahrom 7414846199, Iran 3 Department of Emergency Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran 1473115447, Iran Correspondence should be addressed to Afsoon Emami Naini, emaminaini afsoon@ Received 3 February 2012; Revised 22 March 2012; Accepted 6 April 2012 Academic Editor: Maurizio Muscaritoli Copyright © 2012 Afsoon Emami Naini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In patients on maintenance hemodialysis several factors reduce the body stored carnitine which could lead to dyslipidemia, anemia, and general health in these patients. We evaluated the effect of oral L-carnitine supplementation on lipid profiles, anemia, and quality of life (QOL) in hemodialysis patients. In a randomized, double-blinded, placebo-controlled trial, end-stage renal disease (ESRD) patients on hemodialysis received either L-carnitine 1 g/d (n = 24) or placebo (27 patients) for 16 weeks. At the end